TEL AVIV, Israel, March 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will announce financial results for the fourth quarter and fiscal year ended December 31, 2015 and host a conference call and live audio webcast on Tuesday, March 29, at 8:30 a.m. Eastern Time.
| Tuesday, March 29, 2016 @ 8:30am Eastern Time | |
| Domestic: | 888-428-9480 |
| International: | 719-457-2648 |
| Conference ID: | 3465224 |
| Webcast: | http://edge.media-server.com/m/p/a4mzgp3s |
| Replays, available through April 6, 2016 | |
| Toll Free: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 3465224 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has demonstrated safety in >170 cancer patients and efficacy signals in an `all comers` Ph1 trial as well as in three tumor-specific Ph2 studies. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Ph3 pivotal trial for Recurrent Glioblastoma (rGBM); the trial is being conducted under an FDA Special Protocol Assessment (SPA), fast track and Orphan designation.